Loading data for VNRX — first visit, this takes a few seconds.
VolitionRx Limited
0.31 -0.03 (-8.82%)
0.31 -1.35%
- Capitalisation boursière
- $5.90M
- Volume
- 1.04M
- Prochaine publication des résultats
- Nov 12, 2026
VolitionRx Limited (VNRX) : cours, analyse et données
Valeur intrinsèque
Prévisions des analystes
Prévisions boursières →Derniers résultats
| Signalé | Écart estimé | Changement d’une année sur l’autre | |
|---|---|---|---|
| Chiffre d’affaires | $398.7K | n/a | -1.97% |
| EPS | -$0,59 | +$0,08 | +54.96% |
Métriques
- Cours acheteur
- 0.31
- Chiffre d’affaires (ttm)
- 2.46M
- Résultat net (ttm)
- -26.1M
- 1.09
- -3.85
- n/a
- -0.37
- P/B (ttm)
- -0.12
- P/S (ttm)
- 2.40
- Date des résultats
- Nov 12, 2026
- Cours vendeur
- 0.32
- Volume
- 1,038,115
- Volume moy. (20D)
- 7,748,864
- Ouverture
- 0.34
- Clôture précédente
- 0.34
- Fourchette du jour
- 0.31 - 0.34
- Intervalle de 52 semaines
- 0.31 - 14.80
- Analyste
- n/a
- Objectif de prix
- n/a
- Dividendes
- n/a
- Date ex-dividende
- n/a
À propos de VolitionRx Limited
Voir le profil →VolitionRx Limited, a multi-national epigenetics company, develops blood tests to help detect and monitor a range of cancers, and diseases associated with NETosis in the United States, Europe, and Asia. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets, detects diseases associated with NETosis, such as sepsis; Nu.Q Discover, a solution to profiling nucleosomes. It also provides Nu.Q Cancer for predicting treatment response, monitoring treatment response and disease progression, and amending a patient's cancer treatment regimen; and Capture-PCR and Capture-Seq, which are isolating and capturing circulating tumor-derived DNA from plasma samples for early cancer detection. VolitionRx Limited is headquartered in Henderson, Nevada.
VolitionRx Limited, a multi-national epigenetics company, develops blood tests to help detect and monitor a range of cancers, and diseases associated with NETosis in the United States, Europe, and Asia. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets, detects diseases associated with NETosis, such as sepsis; Nu.Q Discover, a solution to profiling nucleosomes. It also provides Nu.Q Cancer for predicting treatment response, monitoring treatment response and disease progression, and amending a patient's cancer treatment regimen; and Capture-PCR and Capture-Seq, which are isolating and capturing circulating tumor-derived DNA from plasma samples for early cancer detection. VolitionRx Limited is headquartered in Henderson, Nevada.
Industrie Medical Devices
Secteur Healthcare
Date d’introduction Mar 2, 2012
Employés 57
Bourse NYSE American
Symbole boursier VNRX
Site web https://volition.com